|
| Experimental model systems for preclinical research on Waldenström macroglobulinemia |
| |
| View Full Text View/Add Comment Download reader |
| DOI：10.46701/APJBG.2019012019114 |
| KeyWord:IgM+ lymphoplasmacytic lymphoma, human-in-mouse xenografting, genetically engineered mouse model |
| Author | Institution |
| Fumou Sun |
Division of Hematology and Oncology, Department of Medicine |
| Yan Cheng |
Division of Hematology and Oncology, Department of Medicine |
| Siegfried Janz |
Division of Hematology and Oncology, Department of Medicine; Cancer Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA |
|
| Hits: 2059 |
| Download times: 2187 |
| Abstract: |
| Waldenstr?m macroglobulinemia (WM) is an incurable low-grade lymphoplasmacytic lymphoma of mature IgM+ B-lymphocytes that warrants additional research to increase therapeutic options, enhance quality of life, and improve survival of patients with WM. Here we concluded a miniseries of short reviews on the diagnosis and treatment [1], natural history [2] and putative cell-of-origin of WM [3] with a brief survey of preclinical experimental model systems available for fundamental and translational research studies on this enigmatic neoplasm. The model systems comprise of: ① continuous tumor cell lines, three of which are well authenticated and demonstrated to be derived from the patient's index tumor; ② human-in-mouse xenografts that rely on immunodeficient laboratory mice, adapted to carry small fragments of implanted human bone, to provide a suitable microenvironment for incoming lymphoma cells; and ③ genetically engineered mouse models (GEMMs) of neoplastic B-cell development, in which WM-like tumors arise spontaneously in the presence of fully functional innate and adaptive immune systems. Because none of the models developed thus far are perfect, additional efforts are required to achieve a better preclinical representation of disease characteristics of WM. To achieve that goal, the active involvement of basic and clinical research experts from China is called for, so novel drugs and immunotherapies for WM will reach clinics sooner, thereby ensuring the future of patients with WM will be brighter. |
| Close |
|
|
|
